

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



FOSUN INTERNATIONAL LIMITED

(Incorporated in Hong Kong with limited liability under the Companies Ordinance)

(Stock Code: 00656)

ANNOUNCEMENT PROPOSED ISSUE AND LISTING OF H SHARES OF FOSUN PHARMA ON THE HONG KONG STOCK EXCHANGE

This announcement is made pursuant to Rule 13.09 (1) of the Rules Governing the Listing of Securities ("**Listing Rules**") on The Stock Exchange of Hong Kong Limited ("**Hong Kong Stock Exchange**").

The board of directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("**Fosun Pharma**"), a subsidiary of Fosun International Limited (the "**Company**") and whose A shares are listed and traded on the Shanghai Stock Exchange (Stock Code: 600196), passed the resolutions at the 29th meeting (provisional) of the 5th session of the board of directors on 27 February 2011.

The board of directors of the Company would like to draw the attention of its shareholders and the investment public to the following matters, approved, among other things, in the aforesaid board meeting of Fosun Pharma:

I. Proposed Listing of H Shares of Fosun Pharma on the Hong Kong Stock Exchange

It is proposed that Fosun Pharma will offer for subscription and apply for listing of its H shares on the Main Board of the Hong Kong Stock Exchange ("**Proposed Global Offering**").

II. Offering Size

The total number of H shares to be offered under the Proposed Global Offering, which is proposed not to exceed 20% of Fosun Pharma's total issued shares after the completion of the Proposed Global Offering, will be determined by the board of directors of Fosun Pharma in accordance with the requirements under relevant laws and regulations, the regulatory approval and market conditions, subject to the approval of the first extraordinary general meeting of 2011 of Fosun Pharma (the "**Extraordinary General Meeting**") to be held on 16 March 2011. Underwriters (or their authorised representatives) will be granted an over-allotment option to issue no more than 15% of the H shares initially available under the Proposed Global Offering.

III. Timetable

The concrete timetable of the Proposed Global Offering will be determined by the board of directors of Fosun Pharma (as authorised under the Extraordinary General Meeting) with reference to the conditions of the international capital markets and the progress of approval from both the local and overseas regulatory bodies.

The Company will comply with the Listing Rules in respect of the Proposed Global Offering, if and when appropriate.

The Proposed Global Offering is subject to, among other things, the approval of shareholders of Fosun Pharma at the Extraordinary General Meeting and the regulatory approval, and may or may not materialise. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Fosun International Limited
Guo Guangchang
Chairman

Shanghai, the PRC, 28 February 2011

As at the date of this announcement, the executive directors of the Company are Mr. Guo Guangchang, Mr. Liang Xinjun, Mr. Wang Qunbin, Mr. Fan Wei, Mr. Ding Guoqi, Mr. Qin Xuetang and Mr. Wu Ping; the non-executive director is Mr. Liu Benren; and the independent non-executive directors are Dr. Chen Kaixian, Mr. Zhang Shengman and Mr. Andrew Y. Yan.